Thompson W M, Foote R L, Olsen K D, Schaid D J, Grado G L, Buskirk S J, Earle J D
Division of Radiation Oncology, Mayo Clinic Rochester, MN 55905.
Mayo Clin Proc. 1993 Jul;68(7):665-9. doi: 10.1016/s0025-6196(12)60602-8.
From January 1975 through July 1987 at the Mayo Clinic, 16 patients received postoperative adjuvant radiation therapy for squamous cell carcinoma of the tonsil (pathologic stage I in 4 patients, stage III in 3, and stage IV in 9). Follow-up was continued for a minimum of 2 years or until death. At 5 years, overall survival was 74% and disease-free survival was 68% for the entire group of patients. The local-regional control rate at 5 years was 83% for 12 patients with pathologic stage III or IV disease; the 5-year disease-free survival rate was 74%. The results with use of postoperative irradiation for stage III or IV tonsillar cancer seem superior to those for a similar historical group of patients who underwent surgical treatment only. Because the number of patients was small and the analysis was retrospective, our study may have included some undetected bias.
1975年1月至1987年7月期间，在梅奥诊所，16例扁桃体鳞状细胞癌患者接受了术后辅助放疗（4例为病理I期，3例为III期，9例为IV期）。随访持续至少2年或直至死亡。全组患者5年总生存率为74%，无病生存率为68%。12例病理III期或IV期疾病患者的5年局部区域控制率为83%；5年无病生存率为74%。III期或IV期扁桃体癌术后放疗的结果似乎优于仅接受手术治疗的类似历史患者组。由于患者数量少且分析为回顾性，我们的研究可能存在一些未被发现的偏差。
